Cargando…

Cardiac damage in patients with the severe type of coronavirus disease 2019 (COVID-19)

BACKGROUND: Coronavirus disease 2019 (COVID-19) has become a global pandemic. Studies showed COVID-19 affected not only the lung but also other organs. In this study, we aimed to explore the cardiac damage in patients with COVID-19. METHODS: We collected data of 100 patients diagnosed as severe type...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jing, Zhang, Yinghua, Wang, Fang, Liu, Bing, Li, Hui, Tang, Guodong, Chang, Zhigang, Liu, Aihua, Fu, Chunyi, Lv, You, Gao, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7652577/
https://www.ncbi.nlm.nih.gov/pubmed/33167876
http://dx.doi.org/10.1186/s12872-020-01758-w
_version_ 1783607717812764672
author Li, Jing
Zhang, Yinghua
Wang, Fang
Liu, Bing
Li, Hui
Tang, Guodong
Chang, Zhigang
Liu, Aihua
Fu, Chunyi
Lv, You
Gao, Jing
Li, Jing
author_facet Li, Jing
Zhang, Yinghua
Wang, Fang
Liu, Bing
Li, Hui
Tang, Guodong
Chang, Zhigang
Liu, Aihua
Fu, Chunyi
Lv, You
Gao, Jing
Li, Jing
author_sort Li, Jing
collection PubMed
description BACKGROUND: Coronavirus disease 2019 (COVID-19) has become a global pandemic. Studies showed COVID-19 affected not only the lung but also other organs. In this study, we aimed to explore the cardiac damage in patients with COVID-19. METHODS: We collected data of 100 patients diagnosed as severe type of COVID-19 from February 8 to April 10, 2020, including demographics, illness history, physical examination, laboratory test, and treatment. In-hospital mortality were observed. Cardiac damage was defined as plasma hypersensitive troponin I (hsTnI) over 34.2 pg/ml and/or N-terminal-pro brain natriuretic peptide (NTproBNP) above 450 pg/ml at the age < 50, above 900 pg/ml at the age < 75, or above 1800 pg/ml at the age ≥ 75. RESULTS: The median age of the patients was 62.0 years old. 69 (69.0%) had comorbidities, mainly presenting hypertension, diabetes, and cardiovascular disease. Fever (69 [69.0%]), cough (63 [63.0%]), chest distress (13 [13.0%]), and fatigue (12 [12.0%]) were the common initial symptoms. Cardiac damage occurred in 25 patients. In the subgroups, hsTnI was significantly higher in elder patients (≥ 60 years) than in the young (median [IQR], 5.2 [2.2–12.8] vs. 1.9 [1.9–6.2], p = 0.018) and was higher in men than in women (4.2 [1.9–12.8] vs. 2.9 [1.9–7.4], p = 0.018). The prevalence of increased NTproBNP was significantly higher in men than in women (32.1% vs. 9.1%, p = 0.006), but was similar between the elder and young patients (20.0% vs. 25.0%, p = 0.554). After multivariable analysis, male and hypertension were the risk factors of cardiac damage. The mortality was 4.0%. CONCLUSIONS: Cardiac damage exists in patients with the severe type of COVID-19, especially in male patients with hypertension. Clinicians should pay more attention to cardiac damage.
format Online
Article
Text
id pubmed-7652577
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-76525772020-11-10 Cardiac damage in patients with the severe type of coronavirus disease 2019 (COVID-19) Li, Jing Zhang, Yinghua Wang, Fang Liu, Bing Li, Hui Tang, Guodong Chang, Zhigang Liu, Aihua Fu, Chunyi Lv, You Gao, Jing Li, Jing BMC Cardiovasc Disord Research Article BACKGROUND: Coronavirus disease 2019 (COVID-19) has become a global pandemic. Studies showed COVID-19 affected not only the lung but also other organs. In this study, we aimed to explore the cardiac damage in patients with COVID-19. METHODS: We collected data of 100 patients diagnosed as severe type of COVID-19 from February 8 to April 10, 2020, including demographics, illness history, physical examination, laboratory test, and treatment. In-hospital mortality were observed. Cardiac damage was defined as plasma hypersensitive troponin I (hsTnI) over 34.2 pg/ml and/or N-terminal-pro brain natriuretic peptide (NTproBNP) above 450 pg/ml at the age < 50, above 900 pg/ml at the age < 75, or above 1800 pg/ml at the age ≥ 75. RESULTS: The median age of the patients was 62.0 years old. 69 (69.0%) had comorbidities, mainly presenting hypertension, diabetes, and cardiovascular disease. Fever (69 [69.0%]), cough (63 [63.0%]), chest distress (13 [13.0%]), and fatigue (12 [12.0%]) were the common initial symptoms. Cardiac damage occurred in 25 patients. In the subgroups, hsTnI was significantly higher in elder patients (≥ 60 years) than in the young (median [IQR], 5.2 [2.2–12.8] vs. 1.9 [1.9–6.2], p = 0.018) and was higher in men than in women (4.2 [1.9–12.8] vs. 2.9 [1.9–7.4], p = 0.018). The prevalence of increased NTproBNP was significantly higher in men than in women (32.1% vs. 9.1%, p = 0.006), but was similar between the elder and young patients (20.0% vs. 25.0%, p = 0.554). After multivariable analysis, male and hypertension were the risk factors of cardiac damage. The mortality was 4.0%. CONCLUSIONS: Cardiac damage exists in patients with the severe type of COVID-19, especially in male patients with hypertension. Clinicians should pay more attention to cardiac damage. BioMed Central 2020-11-10 /pmc/articles/PMC7652577/ /pubmed/33167876 http://dx.doi.org/10.1186/s12872-020-01758-w Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Li, Jing
Zhang, Yinghua
Wang, Fang
Liu, Bing
Li, Hui
Tang, Guodong
Chang, Zhigang
Liu, Aihua
Fu, Chunyi
Lv, You
Gao, Jing
Li, Jing
Cardiac damage in patients with the severe type of coronavirus disease 2019 (COVID-19)
title Cardiac damage in patients with the severe type of coronavirus disease 2019 (COVID-19)
title_full Cardiac damage in patients with the severe type of coronavirus disease 2019 (COVID-19)
title_fullStr Cardiac damage in patients with the severe type of coronavirus disease 2019 (COVID-19)
title_full_unstemmed Cardiac damage in patients with the severe type of coronavirus disease 2019 (COVID-19)
title_short Cardiac damage in patients with the severe type of coronavirus disease 2019 (COVID-19)
title_sort cardiac damage in patients with the severe type of coronavirus disease 2019 (covid-19)
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7652577/
https://www.ncbi.nlm.nih.gov/pubmed/33167876
http://dx.doi.org/10.1186/s12872-020-01758-w
work_keys_str_mv AT lijing cardiacdamageinpatientswiththeseveretypeofcoronavirusdisease2019covid19
AT zhangyinghua cardiacdamageinpatientswiththeseveretypeofcoronavirusdisease2019covid19
AT wangfang cardiacdamageinpatientswiththeseveretypeofcoronavirusdisease2019covid19
AT liubing cardiacdamageinpatientswiththeseveretypeofcoronavirusdisease2019covid19
AT lihui cardiacdamageinpatientswiththeseveretypeofcoronavirusdisease2019covid19
AT tangguodong cardiacdamageinpatientswiththeseveretypeofcoronavirusdisease2019covid19
AT changzhigang cardiacdamageinpatientswiththeseveretypeofcoronavirusdisease2019covid19
AT liuaihua cardiacdamageinpatientswiththeseveretypeofcoronavirusdisease2019covid19
AT fuchunyi cardiacdamageinpatientswiththeseveretypeofcoronavirusdisease2019covid19
AT lvyou cardiacdamageinpatientswiththeseveretypeofcoronavirusdisease2019covid19
AT gaojing cardiacdamageinpatientswiththeseveretypeofcoronavirusdisease2019covid19
AT lijing cardiacdamageinpatientswiththeseveretypeofcoronavirusdisease2019covid19